PR
Therapeutic Areas
Mirum Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LIVMARLI® (maralixibat) | Cholestatic pruritus in Alagille syndrome (ALGS) | Approved |
| Brelovitug | Chronic Hepatitis Delta Virus (HDV) | Phase 3 |
| Volixibat | Cholestatic Liver Diseases (e.g., Primary Sclerosing Cholangitis) | Phase 2b/3 |
| Investigational Therapies | Cerebrotendinous Xanthomatosis (CTX) | Not Specified |
Leadership Team at Mirum Pharmaceuticals
CP
Chris Peetz
Chief Executive Officer
EB
Eric Bjerkholt
Chief Financial Officer
EC
Erin Campany
Chief People Officer
HJ
Hassan Javanbakht, Ph.D.
Chief Scientific Officer
JG
Jean-Luc Girardet, Ph.D.
Chief Technical Officer
VK
Vinita Kumar
Senior Vice President, Quality
LL
Lara Longpre
Chief Development Officer
JQ
Joanne Quan, M.D.
Chief Medical Officer
DS
Doug Sheehy, JD
Chief Legal Officer
NS
Nancy Shulman, M.D.
Executive Vice President, Clinical